ARAV - Aravive, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Aravive, Inc.

LyondellBasell Tower
Suite 3200 1221 McKinney Street
Houston, TX 77010
United States
936-355-1910
http://www.aravive.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees14

Key Executives

NameTitlePayExercisedYear Born
Mr. Jay P. ShepardPres, CEO & Director818.29kN/A1958
Mr. Vinay ShahChief Financial Officer112.01kN/A1962
Dr. Jeffrey L. ClelandCo-FounderN/AN/A1965
Dr. Joshua Silverman Ph.D.Co-FounderN/AN/AN/A
Dr. Gail F. McIntyreChief Scientific OfficerN/AN/A1963
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aravive, Inc., a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.

Corporate Governance

Aravive, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.